FLT3 and acute myeloid leukemia: It has been 20 years since abnormalities in the FLT3 were first discovered, and the application of FLT3 inhibitors in clinical settings in Japan, Europe, and the United States has resulted in a paradigm shift in the treatment of FLT3-mutated AML.